Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Avigdor

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|July 29, 2017
FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomesTima Davidson, Meirav Kedmi, Abraham Avigdor, et al.
Annals of Hematology|October 14, 2014
Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantationMaya Koren-Michowitz, Hannah Maayan, Arie Apel, et al.
British Journal of Haematology|August 1, 2025
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II studyIvetta Danylesko, Avichai Shimoni, Abraham Avigdor, et al.
Oncotarget|August 25, 2018
STK405759 as a combination therapy with bortezomib or dexamethasone, in <i>in vitro</i> and <i>in vivo</i> multiple myeloma modelsGabriela Rozic, Lena Paukov, Ziv Cohen, et al.
Current Research in Translational Medicine|September 21, 2024
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expressionIvetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 3, 2020
PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone LymphomaTima Davidson, Abraham Avigdor, Yakov Oksman, et al.
Bone Marrow Transplantation|February 28, 2019
Early and late hematologic toxicity following CD19 CAR-T cellsShalev Fried, Abraham Avigdor, Bella Bielorai, et al.
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
Experimental Hematology|March 24, 2007
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphomaAvichai Shimoni, S Tzila Zwas, Yakov Oksman, et al.
Oncogene|October 25, 2003
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cellsOrlev Levy-Nissenbaum, Orit Sagi-Assif, Dina Kapon, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|July 29, 2017
FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomesTima Davidson, Meirav Kedmi, Abraham Avigdor, et al.
Annals of Hematology|October 14, 2014
Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantationMaya Koren-Michowitz, Hannah Maayan, Arie Apel, et al.
British Journal of Haematology|August 1, 2025
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II studyIvetta Danylesko, Avichai Shimoni, Abraham Avigdor, et al.
Oncotarget|August 25, 2018
STK405759 as a combination therapy with bortezomib or dexamethasone, in <i>in vitro</i> and <i>in vivo</i> multiple myeloma modelsGabriela Rozic, Lena Paukov, Ziv Cohen, et al.
Current Research in Translational Medicine|September 21, 2024
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expressionIvetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 3, 2020
PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone LymphomaTima Davidson, Abraham Avigdor, Yakov Oksman, et al.
Bone Marrow Transplantation|February 28, 2019
Early and late hematologic toxicity following CD19 CAR-T cellsShalev Fried, Abraham Avigdor, Bella Bielorai, et al.
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
Experimental Hematology|March 24, 2007
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphomaAvichai Shimoni, S Tzila Zwas, Yakov Oksman, et al.
Oncogene|October 25, 2003
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cellsOrlev Levy-Nissenbaum, Orit Sagi-Assif, Dina Kapon, et al.
Pageof 12